



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 9/14, 33/00, 33/06, 33/08, 33/16, 33/22, 33/42	A1	(11) International Publication Number: WO 99/37287 (43) International Publication Date: 29 July 1999 (29.07.99)
(21) International Application Number: PCT/US99/00391 (22) International Filing Date: 22 January 1999 (22.01.99) (30) Priority Data: 09/012,272 23 January 1998 (23.01.98) US (71) Applicant: USBIOMATERIALS CORPORATION [US/US]; One Progress Boulevard, Box #23, Alachua, FL 32615 (US). (72) Inventors: LEE, Sean; 737 N.W. 84th Street, Gainesville, FL 32607 (US). MEYERS, James, L.; 2610 N.W. 26th Place, Gainesville, FL 32605 (US). (74) Agents: GRUDZIECKI, Ronald, L. et al.; Burns, Doane, Swecker & Mathis, L.L.P., P.O. Box 1404, Alexandria, VA 22313-1404 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: BIOACTIVE GLASS TREATMENT OF INFLAMMATION IN SKIN CONDITIONS		
(57) Abstract This invention relates to a method for treating inflammatory symptoms such as burning, redness, itching, swelling and pain which accompany skin disorders other than wounds of the skin. The method comprising topical application of a topical medicinal composition comprising a non-interlinked particulate bioactive glass mixed with a topical medicinal carrier to the site of the skin disorder.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

-1-

BIOACTIVE GLASS TREATMENT OF INFLAMMATION
IN SKIN CONDITIONS

FIELD OF THE INVENTION

5 This invention relates to a topical treatment and composition which may be applied to mitigate inflammatory symptoms such as burning, redness, itching, swelling and pain which accompany skin disorders, either of an acute or chronic nature.

BACKGROUND OF THE INVENTION

10 Many skin conditions, such as psoriasis, acne, poison ivy and heat rash to name only a few, are accompanied by an inflammation of the epithelium. This often leads to symptoms of burning, redness, itching, swelling and pain at the site. Although the root cause of the disorder varies with the disease, the generic inflammatory response is regulated by leukocyte activity and a host of inflammatory cytokines such as Interleukins and Tumor Necrosis Factors. Cell
15 necrosis, as opposed to cell apoptosis, will release cellular debris into the extracellular environment in such a way as to activate neutrophils and macrophages, the key cells to initiate an inflammatory reaction. These activated cells themselves release a host of cytokines which chemotactically attract more leukocytes and other cells to the site of the inflammation. More information on
20 inflammation, its causes, and its treatment may found in E. Arrigoni - Martelli *Inflammation and Antiinflammatories*, Spectrum Publication, 1977.

In recent years bioactive glasses have been used for a wide variety of health related applications (see Hench, *et al.*, *Life Chemistry Reports*, vol. 13, pp

-2-

187 - 241 (1996)). Copending U.S. Patent application No. 08/715,911 teaches a pharmaceutical composition comprising non-linked particles of bioactive glass, optionally in a carrier which is suitable for topical application. This composition is taught to be useful for promoting healing wounds and improving the structure and appearance of scar tissue as the wounds heal. However, there is no teaching that the composition could be used to reduce the symptoms of inflammation arising from skin disorders (other than wounds), such as allergic reactions and rashes.

10

SUMMARY OF THE INVENTION

The present invention is a method for treating inflammatory symptoms related to various skin disorders other than wounds, comprising topical application of a non-interlinked, particulate bioactive glass mixed with a topical medicinal carrier to the site of the skin disorder.

15

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

As used herein the terms "bioactive glass" or "biologically active glass" mean an inorganic, glass material having an oxide of silicon as a major component and capable of bonding with growing tissue when reacted with physiological fluids. The term "skin disorder" means abnormalities, other than wounds, of the skin which have induced a state of inflammation. Such disorders include, but are not limited to warts acme, dermatitis, hives, psoriasis, rashes, contact allergic reactions, and reactions to insect stings, and bites.

20

The term "wound," as used herein, means an injury wherein the integrity of a patient's skin has been breached, as in the case of a cut or puncture, or where

-3-

the skin has been destroyed by a chemical or thermal burn. "Normal" is used in the sense it is usually used in the medical arts. "Medical practitioner" means one of ordinary skill in the art of treating skin disorders. Typically this person is a physician, although in some cases, it may also be a nurse or physician's associate.

- 5 The term "topical medicinal carrier" includes but is not limited to creams, ointments, gels, transdermal patches and lotions into which are blended therapeutic agents for topical application.

Particulate bioactive glasses in accordance with the present invention typically have the following composition by weight percentage:

10	Compound	percent range
	SiO ₂	40-86
	CaO	10-46
	Na ₂ O	0-35
	P ₂ O ₅	2-15
15	CaF ₂	0-25
	B ₂ O ₃	0-10
	K ₂ O	0-8
	MgO	0-5

wherein the total composition is 100%

- 20 The preferred composition of the bioactive glass for the present invention by weight percentage is:

	Compound	Percent
	SiO ₂	45
	CaO	24.5
25	Na ₂ O	24.5
	P ₂ O ₅	6

-4-

Bioactive glasses and methods of their preparation are well known in the art and several are commercially available.

Particulate, non-linked bioactive glass is preferred in the present invention. That is, the glass is in the form of small, discrete particles, rather than a fused
5 matrix of particles or a fabric (woven or non-woven) of glass fibers. Note that under some conditions the discrete particles of the present invention may tend to cling together because of electrostatic or other forces but are still considered to be non-linked.

The preferred particle size range for the bioactive glass is small and not
10 greater than 90 microns. Particle sizes less than 20 microns as well as less than 2 microns can also be used. Particles of such a small size range generally provide for the advantages of the present invention but do not illicit any undesirable immune response.

There are many topical carriers known to those skilled in the art which may
15 be used in the present invention, and the preferred carrier generally depends upon the specific disorder. The skilled artisans will appreciate that other therapeutic agents such as healing promotion agents, anti-inflammatory agents, antiseptic agents, and topical anesthetic agents may also be added to the composition of the present invention. Example of such agents include but are not limited to
20 corticosteroids, benzocaine and lidocaine.

The bioactive glass and topical treatment can be combined in any
pharmaceutically acceptable carrier to facilitate application to the skin. It is also
within the scope of the present invention to combine the bioactive glass and topical
ointment of the present invention with other treatments such as dressings, etc.

-5-

While not being bound to any particular theory or mechanism, the bioactive glass may also act as an absorbent of several inflammatory cytokines and thus act to shunt the overall inflammatory response in the area. Evidence indicates that reactivity of the bioactive glass releases ions into the extracellular environment which increases the extracellular osmotic pressure. This may reduce epithelial cell swelling and thus help prevent cell necrosis in the area.

Most preferably, particulate bioactive glass and the carrier are mixed just before application to the skin. If the two ingredients are mixed several days prior to application, e.g. one week, the ability of the composition to mitigate the inflammation may be compromised. This problem is particularly acute, if the carrier causes bioactive glass to pre-react in a way that reduces the bioactivity of the glass.

While the ratio of bioactive glass to carrier is not critical, preferably the blend of bioactive glass, other therapeutic agents, and carrier contains about 20 % to about 80 % bioactive glass. The preferred particle size range for the bioactive glass is not greater than about 90 microns is recommended. Particle sizes less than about 10 microns as well as less than about 2 microns can also be used. Particles of such a small size range generally provide for the advantages of the present invention but do not illicit any undesirable immune response. The proportion of other therapeutic agents varies according to the agent and the nature of the application. However, the preferred proportions are such that the amount of the agent administered to the area is in the dosage range approved by the accepted medical practice. The method of the present invention may be used on mammals, such as humans, and therefore is useful in both veterinary and well as human medicine.

-6-

The present invention is administered to a patient in a manner similar to that use for the administration of topical anti-inflammatory compositions now in clinical use. While the exact treatment regimen is at the discretion of the attending medical practitioner, typical treatment comprises liberally applying a
5 film of the bioactive glass containing composition to the inflamed area, optionally with gentle massage to work the composition into the skin. After application of the composition, the injured area is treated according to accepted medical practice, *e.g.*, after applying the composition, the injured area may be covered with a sterile bandage. Of course, in nonhuman mammals treatment would be in
10 accordance with accepted veterinary practice, but would typically be analogous to human treatment.

Treatment frequency is not critical but is typically two to four time daily although supplemental applications may be needed if the patient is active and prone to a high rate of perspiration. Treatment is continued until the attending
15 medical practitioner determines the symptoms of the inflammation are no longer present. A patient being treated according to the method of the present invention may be concurrently treated with supplemental or adjuvant agents, such as oral or injected anti-inflammatory or antibiotic agents.

EXAMPLES

20 Example 1

An individual suffering from psoriasis vulgaris and resulting prolonged inflammation on the arms was treated with a particulate bioactive glass known as "45S5" and having the preferred composition referenced herein above and having
particle size of less than 20 microns blended into an aloe vera based gel. The
25 ratio of bioactive glass to gel was 30 to 60 based on weight. These rashes were chronic and unsuccessfully treated prior to the treatment of this invention. The

-7-

mixture of this invention was applied every 24 hours. After two treatments the itching, swelling and pain had ceased.

Example 2

5 An individual suffering for several years from psoriasis vulgaris on the palms of the hands was treated with a bioactive glass composition as used in Example 1. The rash was chronic and unresponsive to all other clinical treatments prior to the treatment of the present invention. The composition was applied once every 24 hours. After two treatments the itching, swelling and pain had ceased and redness was decreased.

10 Example 3

 An individual suffering from a mildly chronic (18 month) skin rash on the top of the hand whose etiology was not determined was treated with a mixture of particulate bioactive glass composition described in Example 1. Previously, topical steroids alone were applied for 18 months with only moderate, transient
15 success. The mixture of this invention was applied three times every 24 hours. After three treatments the rash had disappeared and did not recur.

-8-

What is claimed is:

1. A method of treating inflammatory symptoms related to skin disorders, other than wounds, in a mammal, comprising topical application to the site of the inflammatory skin disorder an inflammation treating amount of non-interlinked, particulate bioactive glass, the bioactive glass having the following compositional weight percentages:

	SiO ₂	40-86
	CaO	10-46
10	Na ₂ O	0-35
	P ₂ O ₅	2-15
	CaF ₂	0-25
	B ₂ O ₃	0-10
	K ₂ O	0-8
15	MgO	0-5.

2. The method of Claim 1, further comprising applying along with the bioactive glass, topical creams, ointments, gels, or lotions.

3. The method of Claim 1, further comprising applying along with the bioactive glass, one or more additional therapeutic agents.

4. The method of Claim 3 wherein one or more therapeutic agents are selected from the group consisting of healing promotion agents, anti-inflammatory agents, antiseptic agents, and topical anesthetic agents.

-9-

5. The method of claim 1, wherein the composition of the bioactive glass is:

	Compound	Percent
	SiO ₂	45
5	CaO	24.5
	Na ₂ O	24.5
	P ₂ O ₅	6

6. The method of claim 1, wherein the bioactive glass has a particle size range less than about 90 microns.

10 7. The method of claim 1, wherein the bioactive glass has a particle size range less than about 20 microns.

8. The method of claim 1, wherein the bioactive glass has a particle size range less than about 2 microns.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/00391

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 9/14, 33/00, 33/06, 33/08, 33/16, 33/22, 33/42.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/400, 401, 484, 489, 601, 602, 606, 657, 660, 675, 688, 692, 722, 724; 514/830, 859, 861, 862, 863, 864, 865, 886, 887, 951.

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y,P	US 5,728,753 A (BONFIELD et al.) 17 March 1998, see column 2, lines 24-29 and 55-56, column 3, line 27.	1-8
Y,P	US 5,766,611 A (SHIMONO et al.) 16 June 1998, see claims 1-2.	1-8
Y,P	US 5,840,290 A (HENCH et al.) 24 November 1998, column 2, lines 16-19 and 29-33, column 3, lines 27-67, claim 3.	1-8

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	* T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
* A* document defining the general state of the art which is not considered to be of particular relevance	* X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
* B* earlier document published on or after the international filing date	* Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
* L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	* A* document member of the same patent family
* O* document referring to an oral disclosure, use, exhibition or other means	
* P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

29 APRIL 1999

Date of mailing of the international search report

14 MAY 1999

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

JOHN PAK

Telephone No. 308-1235

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/00391

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

424/400, 401, 484, 489, 601, 602, 606, 657, 660, 675, 688, 692, 722, 724; 514/830; 859, 861, 862, 863, 864, 865, 886, 887, 951.

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

STN ONLINE, FILES CAPLUS, WPIDS. SEARCH TERMS: skin, skin disorder#, acne, dermatitis, hives, psoriasis, rash?, contact allerg?, insect bite#, wound#, glass, silicon dioxide, SiO_2 , calcium oxide, CaO , P_2O_5 , phosphorous pentoxide, bioactive glass, biologically active glass, not (bone# or cement?).